drugset
Drugs / VERU-100
last change Jan 2023 re-read 3 minutes ago

VERU-100

Developed for
prostate adenocarcinoma
Investigated by
Veru Inc.

Trials 1

today NCT04843319 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04843319 Jun 2021 → Jan 2023 prostate adenocarcinoma Veru Inc. Terminated No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2021-06-10 Veru Inc. Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer verupharma.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VERU-100 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04843319 ↗